Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03876106 · ClinicalTrials.gov registry record · Phase 1
A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions
A Phase 1 study of EGFR Inhibitor Induced Acneiform Lesions, sponsored by Lutris Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 10
- Enrollment target
- 6
- Study locations
NCT03876106 is a Phase 1 study of EGFR Inhibitor Induced Acneiform Lesions that has completed, run by Lutris Pharma. The registered enrollment target is 10 participants. The trial reports 6 study locations across 5 states.
The verdict
NCT03876106, a Phase 1 study of EGFR Inhibitor Induced Acneiform Lesions, has completed, sponsored by Lutris Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 10 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this phase 1, multicenter study is to evaluate the safety, tolerability and preliminary efficacy of LUT014 in adult metastatic colorectal cancer patients with EGFR Inhibitor induced acneiform lesions
Conditions Studied
Interventions
- DRUG LUT014
Study Locations (6)
Other
- Rabin Medical Center - Petah Tikva
- Sheba Medical Center - Ramat Gan
California
- UCLA Health Santa Monica - Cancer Care - Los Angeles
Missouri
- Washington University School of Medicine-Dermatology - St Louis
New York
- Memorial Sloan Kettering Cancer Center - New York
Texas
- MD Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-08-21 |
| Est. Completion | 2020-11-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03876106
The ClinicalTrials.gov registry entry for NCT03876106 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lutris Pharma, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with EGFR Inhibitor Induced Acneiform Lesions appearing as the primary indexed condition, and to 1 intervention - of which LUT014 is the first listed.
NCT03876106 reports 6 study locations spanning 5 distinct geographic areas - top geographies include Other, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT03876106 about?
NCT03876106 is a clinical study titled "A Study of LUT014 in Patients With Metastatic Colorectal Cancer With EGFR Inhibitor Induced Acneiform Lesions". The purpose of this phase 1, multicenter study is to evaluate the safety, tolerability and preliminary efficacy of LUT014 in adult metastatic colorectal cancer patients with EGFR Inhibitor induced acneiform lesions
What is the current status of trial NCT03876106?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 10 participants. The study started on 2019-08-21. Estimated completion is 2020-11-18.
What conditions does trial NCT03876106 study?
This clinical trial studies the following conditions: EGFR Inhibitor Induced Acneiform Lesions.
What interventions are being tested in trial NCT03876106?
The interventions under investigation include: LUT014 (DRUG).
Who is sponsoring clinical trial NCT03876106?
This trial is sponsored by Lutris Pharma, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03876106 being conducted?
This trial has 6 study locations across California, Missouri, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.